Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: A systematic review and additional economic modelling of subgroup analyses

Health Technology Assessment

Volumn 15, Issue 5, 2011, Pages

  Wang, D ^a   Bayliss, S ^b   Meads, C ^c  

^a University of Birmingham ^*

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

BRONCHITIS; CHILD; CHRONIC LUNG DISEASE; CIGARETTE SMOKING; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; COMORBIDITY; CONGENITAL HEART DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYANOSIS; DATA BASE; DISEASE SEVERITY; DRUG COST; ECONOMIC EVALUATION; GESTATIONAL AGE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; INFANT; MEDICAL LITERATURE; MEDICAL TECHNOLOGY; NONHUMAN; PREMATURITY; PROGNOSIS; PUBLIC HEALTH PROBLEM; PUBLIC HEALTH SERVICE; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; SYSTEMATIC REVIEW;

EID: 79951562634     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta15050     Document Type: Review

References (28)

1. Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 2008;12(36).
2. Fjaerli HO, Farstad T, Bratlid D. Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000: a population-based retrospective study. BMC Pediatrics 2004;4(25):1-7.
3. Cabalka AK. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Pediatr Infect Dis J 2004;23:S41-S45.
4. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 59. London: BMA and RPS; 2010.
5. Anon. Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence; 2009.
6. Rietveld E, Vergouwe Y, Steyerberg EW, Huysman MW, de Groot R, Moll HA, et al. Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule. Pediatr Infect Dis J 2006;25(3):201-7.
7. Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child 2004;89(10):961-5.
8. Feltes TF, Sondheimer HM. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. Expert Opin Biol Ther 2007;7(9):1471-80.
9. Kristensen K, Stensballe LG, Bjerre JV, Roth D, Fisker N, Kongstad T, et al. Risk factors for RSV hospitalisation in children with heart disease. Arch Dis Child 2009;94(10):785-9.
10. Simoes EA, Sondheimer HM, Top FH, Jr, Meissner HC, Welliver RC, Kramer AA, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998;133(4):492-9.
11. Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Domenech E, Figueras-Aloy J, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J 2000;19(7):592-7.
12. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Jr, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143(4):532-40.
13. The IMpact-RSV Study Group. Palivisumab, a humanised respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3):531-7.
14. Carbonell-Estrany X, Quero J, IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001;20(9):874-9.
15. Eriksson M, Bennet R, Rotzen-Ostlund M, von Sydow M, Wirgart BZ. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr 2002;91(5):593-8.
16. Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004;23(9):815-20.
17. Simoes EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, et al. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 2008;9:78.
18. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jimenez J, Fernandez-Colomer B, Guzman-Cabanas J, Echaniz-Urcelay I, et al. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008;27(9):788-93.
19. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 2008;28(7):511-17.
20. Grimwood K, Cohet C, Rich FJ, Cheng S, Wood C, Redshaw N, et al. Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand. Epidemiol Infect 2008;136(10):1333-41.
21. Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, et al. The Pediatric Investigators Collaborative Network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23(9):806-14.
22. Liese J. Comment on the Austrian consensus paper on prophylaxis of RSV infection with palivizumab and post-RSV respiratory tract disease. Monatsschrift fur Kinderheilkunde 2008;156(4):384.
23. Nielsen HE, Siersma V, Andersen S, Gahrn-Hansen B, Mordhorst CH, Norgaard-Pedersen B, et al. Respiratory syncytial virus infection--risk factors for hospital admission: a case-control study. Acta Paediatr 2003;92(11):1314-21.
24. Rossi GA, Medici MC, Arcangeletti MC, Lanari M, Merolla R, Paparatti UD, et al. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr 2007;166(12):1267-72.
25. Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162(4):230-6.
26. Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PA, Hagan J, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004;89(7):673-8.
27. Yount LE, Mahle WT, Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114(6):1606-11.
28. Nuijten MJC, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: A UK analysis. Pharmacoeconomics 2007;25(1):55-71.